Hikma Pharmaceuticals Plc Notice of Results
February 05 2024 - 3:46AM
RNS Regulatory News
RNS Number : 0216C
Hikma Pharmaceuticals Plc
05 February 2024
Notice of preliminary
results
London, 5 February 2024
- Hikma Pharmaceuticals
PLC (Hikma, Group), will announce its preliminary financial results
for the year ended 31 December 2023 on Thursday 22 February
2024.
A recording of the 2023 Preliminary
Results presentation and slide deck will be available on the
Group's website at www.hikma.com from 7:00am GMT. Hikma will also hold a Q&A call for
analysts at 12:00pm GMT, and a recording will be made available on
the Company's website.
To join the call please, please
register your attendance in advance by clicking
here.
- ENDS
-
Enquiries
Hikma Pharmaceuticals
PLC
|
Susan Ringdal
EVP, Strategic Planning and Global
Affairs
|
+44 (0)20 7399 2760/ +44 (0)7776
477050
|
|
Guy Featherstone
Associate Director, Investor
Relations
|
+44 (0)20 3892 4389/ +44 (0)7795
896738
|
|
Layan Kalisse
Senior Associate, Investor
Relations
|
+44 (0)20 7399 2788/ +44 (0)7970
709912
|
Teneo (Press):
Charles Armitstead / Rob
Yates
+44 (0)7703 330 269/ +44 (0)7715 375443
About Hikma
Hikma Pharmaceuticals PLC (LSE: HIK)
(NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI:549300BNS685UXH4JI75) (rated
BBB-/stable S&P and BBB-/positive Fitch)
Hikma helps put better health within
reach every day for millions of people around the world. For more
than 45 years, we've been creating high-quality medicines and
making them accessible to the people who need them. Headquartered
in the UK, we are a global company with a local presence across
North America, the Middle East and North Africa (MENA) and Europe,
and we use our unique insight and expertise to transform
cutting-edge science into innovative solutions that transform
people's lives. We're committed to our customers, and the people
they care for, and by thinking creatively and acting practically,
we provide them with a broad range of branded and non-branded
generic medicines. Together, our 8,800 colleagues are helping to
shape a healthier world that enriches all our communities. We are a
leading licensing partner, and through our venture capital arm, are
helping bring innovative health technologies to people around the
world. For more information, please visit:
www.hikma.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
NORDZGGZRKKGDZG
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Oct 2024 to Nov 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Nov 2023 to Nov 2024
